Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells

Wang,Han; Zhong,Jianhua; Wu,Chenglong; Liu,Yang; Zhang,Jinghua; Zou,Xiaowen; Chen,Yan; Su,Jinfeng; Yang,Gang; Zhong,Yuantang; Tang,Aifa

doi:10.3892/or.2017.5711

Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells

Authors:
- Han Wang
- Jianhua Zhong
- Chenglong Wu
- Yang Liu
- Jinghua Zhang
- Xiaowen Zou
- Yan Chen
- Jinfeng Su
- Gang Yang
- Yuantang Zhong
- Aifa Tang
View Affiliations

Affiliations: Shenzhen Second People's Hospital, Clinical Medicine College of Anhui Medical University, Shenzhen, Guangdong 518039, P.R. China, Department of Urinary Surgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518037, P.R. China, Guangzhou Medical University, Guangzhou, Guangdong 511436, P.R. China
Published online on: June 12, 2017 https://doi.org/10.3892/or.2017.5711
Pages: 917-925

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stromal antigen 2 (STAG2) is a subunit of the cohesion complex that plays an important role in the normal segregation of sister chromatids during mitosis or meiosis. However, the effect of STAG2 on the bladder cancer cell proliferation, migration, and invasion has not yet been fully clarified. In this study, we aimed to characterize STAG2 expression and functional significance in BC and adjacent normal tissue. Notably, STAG2 expression was markedly lower in BC cells and tumor tissues than their normal counterparts at the gene and protein levels. Moreover, clinicopathological analysis showed that the low STAG2 expression is associated with TNM stage. Functional analysis demonstrated that STAG2 overexpression attenuated cell proliferation via G1-phase arrest, invasion, and migration, and promoted apoptosis in BC cell lines, while the opposite was observed with STAG2 knockdown cells. Furthermore, STAG2 overexpression upregulated E-cadherin, caspase-3, and caspase-7 and downregulated vimentin, matrix metalloproteinase (MMP)2, and MMP9. Collectively, these data suggest that STAG2 acts as a tumor suppressor gene in bladder cancer and may be a potential therapeutic target in BC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, et al: Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 97:997–1001. 2006. View Article : Google Scholar : PubMed/NCBI
3	Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: How far have we come? CA Cancer J Clin. 60:244–272. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
5	Sanchez-Carbayo M, Socci ND, Lozano J, Saint F and Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 24:778–789. 2006. View Article : Google Scholar : PubMed/NCBI
6	Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, et al: National Comprehensive Cancer Network (NCCN): Bladder cancer. J Natl Compr Canc Netw. 11:446–475. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bolenz C and Lotan Y: Molecular biomarkers for urothelial carcinoma of the bladder: Challenges in clinical use. Nat Clin Pract Urol. 5:676–685. 2008. View Article : Google Scholar : PubMed/NCBI
8	Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, et al: Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 45:1459–1463. 2013. View Article : Google Scholar : PubMed/NCBI
9	Darwiche N, Freeman LA and Strunnikov A: Characterization of the components of the putative mammalian sister chromatid cohesion complex. Gene. 233:39–47. 1999. View Article : Google Scholar : PubMed/NCBI
10	Taylor CF, Platt FM, Hurst CD, Thygesen HH and Knowles MA: Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet. 23:1964–1974. 2014. View Article : Google Scholar : PubMed/NCBI
11	Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, et al: Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 333:1039–1043. 2011. View Article : Google Scholar : PubMed/NCBI
12	Djos A, Fransson S, Kogner P and Martinsson T: Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene. BMC Med Genet. 14:1022013. View Article : Google Scholar : PubMed/NCBI
13	Kim MS, Kim SS, Je EM, Yoo NJ and Lee SH: Mutational and expressional analyses of STAG2 gene in solid cancers. Neoplasma. 59:524–529. 2012. View Article : Google Scholar : PubMed/NCBI
14	Chung NG, Kim MS, Yoo NJ and Lee SH: Somatic mutation of STAG2, an aneuploidy-related gene, is rare in acute leukemias. Leuk Lymphoma. 53:1234–1235. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, et al: Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 45:1232–1237. 2013. View Article : Google Scholar : PubMed/NCBI
16	Losada A, Yokochi T, Kobayashi R and Hirano T: Identification and characterization of SA/Scc3p subunits in the Xenopus and human cohesin complexes. J Cell Biol. 150:405–416. 2000. View Article : Google Scholar : PubMed/NCBI
17	Jessberger R: Cohesin's dual role in the DNA damage response: Repair and checkpoint activation. EMBO J. 28:2491–2493. 2009. View Article : Google Scholar : PubMed/NCBI
18	Balbás-Martínez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Márquez M, Vazquez M, Lapi E, Castro-Giner F, Beltran S, Bayés M, et al: Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet. 45:1464–1469. 2013. View Article : Google Scholar : PubMed/NCBI
19	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
20	Cha K, Hadjiiski L, Chan HP, Caoili EM, Cohan RH and Zhou C: CT urography: Segmentation of urinary bladder using CLASS with local contour refinement. Phys Med Biol. 59:2767–2785. 2014. View Article : Google Scholar : PubMed/NCBI
21	Xiao T, Wallace J and Felsenfeld G: Specific sites in the C terminus of CTCF interact with the SA2 subunit of the cohesin complex and are required for cohesin-dependent insulation activity. Mol Cell Biol. 31:2174–2183. 2011. View Article : Google Scholar : PubMed/NCBI
22	Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, et al: Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 45:1428–1430. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cormio L, Sanguedolce F, Massenio P, Di Fino G, Selvaggio O, Bufo P and Carrieri G: Osseous metaplasia within a urothelial bladder cancer nodal metastasis: A case report. Anal Quant Cytopathol Histpathol. 36:117–119. 2014.PubMed/NCBI
24	Zhao H, Yuan X, Jiang J, Wang P, Sun X, Wang D and Zheng Q: Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-кB activity. Basic Clin Pharmacol Toxicol. 115:527–533. 2014. View Article : Google Scholar : PubMed/NCBI
25	Li J and Yuan J: Caspases in apoptosis and beyond. Oncogene. 27:6194–6206. 2008. View Article : Google Scholar : PubMed/NCBI